CARDIFF, CA--(MARKET WIRE)--Apr 2, 2008 -- NI Research has released the April issue of NeuroInvestment. The issue features a review of Huntington's, a disorder whose monogenic cause and inexorable, horrific course has made it the premier example of why people choose to not have genetic testing. There is at present no approved treatment, though a symptomatic treatment aimed at choreiform movement, Prestwick Pharmaceuticals' tetrabenazine, is likely to be approved by the FDA.

The contents of the April NeuroInvestment include:

 
     1)  Huntington's programs covered in the review include those from
         Medivation, Avicena Group, Cortex (AMEX:COR - News), EnVivo, Ceregene,
         and Accera.
     2)  A review of Neurocrine Biosciences (NasdaqGS:NBIX - News), whose formerly
         robust pipeline has suffered with the indiplon debacle and the
         failure of the first CRF antagonist trial, run by partner GSK.
     3)  'Honey. I Shrunk the Phase II': Commentary about the growing trend
         towards  miniaturized Phase II programs, and why it is a bad idea.
         Examples cited include programs from Astra Zeneca, Medivation,
         Neurochem, Neuro-Hitech, Baxter, Corcept, and D-Pharm.
     4)  An appraisal of the vigabatrin anti-addiction program being run by
         Catalyst Pharmaceuticals.

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year corporate subscription is $1600, email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three-month trial subscription is US$600.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, and the Private CNS Company Review since 2003. In 2007, NI Research launched an annual compendium of all neuro-oriented R&D programs organized by disorder, CNS Disorders/Therapeutics. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies.

     Contact:
     NI Research
     P.O. Box 1028, Cardiff CA 92007
     760.230.2581
     E-mail: Email Contact
     http://www.niresearch.com
     http://www.neuroinvestment.com